Amy Kruse, PhD
Scientific Advisor
Dr. Amy Kruse is a neuroscientist-turned-investor who pairs deep scientific expertise with a keen eye for commercial pathways in neurotechnology. As General Partner and Chief Investment Officer of Satori Neuro and a Venture Partner at Prime Movers Lab, she directs capital to companies advancing mental-health, brain–computer-interface, and human-augmentation solutions. She currently serves on the boards of Cognixion, Paradromics, Gilgamesh Pharmaceuticals, Attune Neurosciences, Morphoceuticals, Dimension Inx, and TARA Mind.
Earlier in her career, Dr. Kruse launched DARPA’s first performance-oriented neuroscience programs, delivering breakthroughs in augmented cognition, accelerated learning, and neuromodulation for U.S. defense and intelligence agencies. She later scaled innovation as Chief Scientific Officer of Optios and as Vice President and Chief Technology Officer at Cubic Global Defense after its acquisition of Intific, broadening each organization’s R&D capabilities and IP portfolios.
A frequent advisor to NIH Blueprint MedTech, BrainMind, the National Academies, and the Defense Science Board, Dr. Kruse holds a PhD in Neuroscience from the University of Illinois Urbana-Champaign. At NeuroEM, she leverages her unique blend of translational insight and investment acumen to guide clinical and wellness strategies and to accelerate the path from laboratory discovery to market-ready neurotechnology.